Concepedia
Statistics
Publications
12
Citations
759
H-Index
Active since
1999
Affiliations
Novartis (United States)(Current)
Novartis (Switzerland)
University of Pennsylvania
University of Rochester Medical Center
Children's Hospital of Philadelphia
Manuel Litchman is an author at Novartis (United States) specializing in chemotherapy, oncology, and pharmacology.
Publications per year
1999–2014
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
Ranjana H. Advani, Hussain I. Saba, Martin S. Tallman et al. · Blood · 1999 · 149 citations
Medicine, Oncology, Pharmacology +16
Ranjana H. Advani, Hussain I. Saba, Martin S. Tallman et al. · Blood · 1999 · 123 citations
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
Ranjana H. Advani, George A. Fisher, B L Lum et al. · PubMed · 2001 · 82 citations
Pharmacy, Pharmacology, Pharmacotherapy +17
Phase I Study of Paclitaxel in Combination With a Multidrug Resistance Modulator, PSC 833 (Valspodar), in Refractory Malignancies
Paula M. Fracasso, Peter Westerveldt, Carole A. Fears et al. · Journal of Clinical Oncology · 2000 · 82 citations
Pharmacy, Pharmacokinetics, Pharmacology +17
Phase I/II Study of the P-Glycoprotein Modulator PSC 833 in Patients With Acute Myeloid Leukemia
R T Dorr, Chatchada Karanes, Catherine Spier et al. · Journal of Clinical Oncology · 2001 · 82 citations
Medicine, Oncology, Pharmacology +17
1–5 of 12